After Sanofi, Novo Nordisk, Lilly has entered the Chinese Diabetes Market

Source: pharmasia news 2016-4-5 Beijing - as China's pharmaceutical market matures and sales of high-end top three hospitals stagnate, multinational pharmaceutical companies are extending their tentacles to county-level hospitals where both hope and challenge coexist This trend is particularly urgent in view of China's overall economic downturn and the tightening of drug control due to the shortage of medical insurance costs Lilly pharmaceutical is a foreign pharmaceutical company newly invested in the low-end market of China The U.S company launched Lilly's leap on March 15, extending diabetes care to 13 provinces across the country Lilly said in the statement that its goal is to connect patients in these areas with health care institutions so that they can have access to medication, including high-quality insulin The campaign also includes public awareness, doctor training and medical consultation To this end, Lilly China established a new business unit - Diabetes basic medical business unit in early 2015, and promoted it to the basic level market with the help of "3D" model, a lilly China leap spokesman told "Asia Pharmaceutical Company" The 3D model includes diabetes care partners, diabetes trainers and salesmen "In cooperation with provincial governments and medical institutions in China, leap and thought leaders jointly held diabetes treatment training meetings to provide important medical tools for medical staff," the company said The role of diabetes trainers is to provide educational support to the people at risk of diabetes or diabetic patients through the customer service center, so that they can benefit from it Market challenges China is a region with high incidence of chronic diseases, and the population of diabetes continues to increase According to the International Diabetes Federation, there are nearly 100 million diabetics in China, accounting for about 10% of the total population Diabetes management is more challenging in rural areas, patients rarely carry out blood glucose testing, it is difficult to control the development of diabetes to more serious complications In fact, by 2030, the burden of diabetes and its complications in China is expected to reach US $132 billion per year Lilly explained that in view of the high incidence rate and the lack of public awareness, China was chosen as the first country to launch the LEAP project The complexity of the problem also lies in China's continued dependence on older diabetes drugs Metformin is the first-line oral treatment drug with the largest prescription in China, accounting for about 38% of the market share of diabetes drugs, compared with only 1% in the United States, a study by the University of England found Multinational pharmaceutical companies show their own magic power Therefore, it is not surprising that major manufacturers of diabetes drugs, including Sanofi and Novo Nordisk, have already begun to enter China's primary county hospital market Novo Nordisk cooperates with the Ministry of health to carry out a three-year training program for doctors in county hospitals, which is then transferred to online training According to the ranking data of Boston Consulting Company, the Danish company has firmly controlled the market share of county-level hospitals by focusing on a single target of insulin and actively participating in bidding with domestic competitors At the same time, Sanofi also set up a grass-roots medical department in 2012 and extended its tentacles to nine provinces and cities in China Since then, the French company has expanded the operation to 500 counties and cities in 17 provinces Unlike Novo Nordisk and Sanofi, Lilly claims that it will focus on small county hospitals and community and township hospitals through leap project, and its market scale even exceeds that of county hospitals Lilly: with the help of the patient assistance program (Pap), Lilly has transformed its market accessibility program into a more sustainable value sharing model, whose core is to exchange price for quantity "Leap is a low return business model aimed at improving the accessibility of effective diabetes treatment and expanding the scope and impact of diabetes drugs and services," the company said Lilly executives have recently trumpeted their strategy of winning by volume At the company's fourth quarter revenue meeting, HIL Johnson, vice president of investor relations, said Lilly's pharmaceutical revenue in China increased by 2% and its sales increased by 5% Its best-selling antidiabetic drug, insulin laiproline, rose 15% in the quarter Andrew Hodge, President of Lilly China, pointed out that "leap is a new way of trial and operation, and I believe that as part of Lilly China's commitment to improving China's health, by creating and sharing permanent values, more and more people's lives will be more beautiful and better." "These provinces are the first step towards our goal, and we plan to expand to other provinces and cities in the next two years, and possibly to other countries and other treatment areas in the future," Lilly said